Understanding the genes for Parkinson's disease
Lead Research Organisation:
University College London
Department Name: Institute of Neurology
Abstract
We now know many of the genes which cause and predispose to Parkinson's disease but for many others, we only know their chromosomal position. In this grant we seek to find these genes and work out how the function of all the genes for the disease relate to each other. We already know that many of the genes for the disease are involved in two related processes: autophagy (how the cell removes damages cell components and proteins) and mitophagy (how the cell removes damaged mitochondria). We will assess whether these new genes are in the same pathways or if there are other relevant pathways involved in the disease Finally, we will develop cellular assays for these pathways so that we can work towards developing drugs which correct the defects we have identified.
Technical Summary
Parkinson's disease is the most common neurodegenerative movement disorder, affecting in access of 120,000 individuals in the United Kingdom, and is uniformly fatal with no disease course modifying therapy available. Genome wide association (GWA) studies have been outstandingly successful in identifying regions of the human genome that are associated with increased risk for a wide range of common human disorders. This is true for Parkinson's disease, where in excess of twenty risk loci have been identified. The major challenge for both academic and industrial researchers is to translate the identification of these genomic regions into biological insights into the molecular aetiology of Parkinson's, which in to turn can inform drug development efforts in this area. To achieve this, the causative variants responsible for the WG association - in most cases likely to be alterations in specific genes - need to be identified and characterized. In this proposal we will use gene expression and splicing analysis to assess the functional role of genes implicated by PD GWA studies, combined with cellular and in vivo studies, to take the key next steps required for evaluation of the role of implicated genes in the molecular pathogenesis of PD and their status as putative drug targets.
Planned Impact
The genetic and functional characterization of genetic loci implicated in the pathogenesis of idiopathic Parkinson's disease by genome wide association studies will have important implications and impact outside of an immediate academic audience.
With more than 120,000 people in the UK currently with Parkinson's, there is an urgent health and economic demand for new treatments. The impact of Parkinson's disease will increase over the coming decades as the UK population ages, emphasising the urgency of developing therapies for this disorder.
We will start by precisely identifying the genes for the disorder and their genetic mechanism through gene expression analysis in parallel with our work outside this proposal in which we are carrying out sequence analysis of PD cases. This genetic, gene expression and bioinformatic work will tell PD researchers including in the pharma industry the biochemical players in the pathways to disease and tell us whether, for each of the genes, we should consider gain or loss or change of function as the pathogenic mechanism.
From our and others previous work, we already know three pathways which are involved in the disorder: autophagy, mitophagy and endosomal pathways. We will continue to explore the role of the known PD genes and mutations on these pathways and seek to identify other molecular components of these pathways. This process will both be guided by the genetic analysis above and equally will guide the genetics as interactors identified in this work may be novel PD loci.
As we develop a deeper cellular understanding of the pathogenic biochemical networks we will develop assays which we will convert to medium throughput assays to enable screening for the compounds which perturb these networks. This information will feed into drug development programs in the academic and pharmaceutical sector, providing a bridge over the gap between the basic genetic insights into PD and translational efforts to produce novel therapies.
The development of disease modifying therapies based upon data generated by this study will have major ramifications for the pharmaceutical sector, the National Health Service and, most importantly, individuals with Parkinson's or at risk of developing the disease. While it is difficult to quantify the impact of a disorder such as Parkinson's on the nation, a recent study (Findley LJ, Parkinsonism and Related Disorders 13: S8-S12, 2007) provides an estimate of between £449 million and £3.3 billion to the UK economy. DiLuca and Olesen (Neuron 82: 1205-1208) estimate the cost of Parkinson's to the European economy as being close to £10 billion (with £5 billion being in direct health care costs), and so it is clear that a disease modifying therapy slowing the disease course or delaying the age of onset would have a major impact on the health and wealth of the United Kingdom. The major challenge for the pharmaceutical industry in the field of neurodegeneration with regarding to developing such a therapy has been to identify clear drug targets, a contrast with the field of cancer biology where a genetic approach has yielded a number of tractable targets. In PD, the number of clear disease modifying drug targets has been limited to a handful, including three (SNCA, LRRK2, and GBA) that have had their status reinforced by their identification by GWA studies for PD. To proceed from a list of circa 20 disease associated loci to a tractable and rationally stratified list of potential drug targets, a critical and required step is the thorough characterization of these loci. This proposal provides a structured and detailed series of work packages to directly address this need.
With more than 120,000 people in the UK currently with Parkinson's, there is an urgent health and economic demand for new treatments. The impact of Parkinson's disease will increase over the coming decades as the UK population ages, emphasising the urgency of developing therapies for this disorder.
We will start by precisely identifying the genes for the disorder and their genetic mechanism through gene expression analysis in parallel with our work outside this proposal in which we are carrying out sequence analysis of PD cases. This genetic, gene expression and bioinformatic work will tell PD researchers including in the pharma industry the biochemical players in the pathways to disease and tell us whether, for each of the genes, we should consider gain or loss or change of function as the pathogenic mechanism.
From our and others previous work, we already know three pathways which are involved in the disorder: autophagy, mitophagy and endosomal pathways. We will continue to explore the role of the known PD genes and mutations on these pathways and seek to identify other molecular components of these pathways. This process will both be guided by the genetic analysis above and equally will guide the genetics as interactors identified in this work may be novel PD loci.
As we develop a deeper cellular understanding of the pathogenic biochemical networks we will develop assays which we will convert to medium throughput assays to enable screening for the compounds which perturb these networks. This information will feed into drug development programs in the academic and pharmaceutical sector, providing a bridge over the gap between the basic genetic insights into PD and translational efforts to produce novel therapies.
The development of disease modifying therapies based upon data generated by this study will have major ramifications for the pharmaceutical sector, the National Health Service and, most importantly, individuals with Parkinson's or at risk of developing the disease. While it is difficult to quantify the impact of a disorder such as Parkinson's on the nation, a recent study (Findley LJ, Parkinsonism and Related Disorders 13: S8-S12, 2007) provides an estimate of between £449 million and £3.3 billion to the UK economy. DiLuca and Olesen (Neuron 82: 1205-1208) estimate the cost of Parkinson's to the European economy as being close to £10 billion (with £5 billion being in direct health care costs), and so it is clear that a disease modifying therapy slowing the disease course or delaying the age of onset would have a major impact on the health and wealth of the United Kingdom. The major challenge for the pharmaceutical industry in the field of neurodegeneration with regarding to developing such a therapy has been to identify clear drug targets, a contrast with the field of cancer biology where a genetic approach has yielded a number of tractable targets. In PD, the number of clear disease modifying drug targets has been limited to a handful, including three (SNCA, LRRK2, and GBA) that have had their status reinforced by their identification by GWA studies for PD. To proceed from a list of circa 20 disease associated loci to a tractable and rationally stratified list of potential drug targets, a critical and required step is the thorough characterization of these loci. This proposal provides a structured and detailed series of work packages to directly address this need.
Publications
Cogo S
(2017)
Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.
in Expert opinion on therapeutic targets
Cogo S
(2022)
Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins.
in Neurobiology of disease
Cogo S
(2022)
The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation
in Brain Research
Costa B
(2020)
C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts.
in Neurology
D'Souza H
(2020)
Differential Associations of Apolipoprotein E e4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome.
in JAMA network open
Dewan R
(2020)
Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
in SSRN Electronic Journal
Title | Additional file 10: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Functional blocks supporting syndrome-specific coherent patterns for PD, FTD and PS. Each semantic class is represented at the bottom of the x axis. Each functional block is found at the top of the x axis. The contribution of each syndrome to each semantic class is defined by colour-coded dots representing single GO terms within each semantic class (PD: red dots, FTD blue dots and PS: orange dots). The pie charts represent the relative distribution of different semantic classes per functional block for either syndrome. (JPG 228 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_10_of_Stratification_of_candidat... |
Title | Additional file 10: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Functional blocks supporting syndrome-specific coherent patterns for PD, FTD and PS. Each semantic class is represented at the bottom of the x axis. Each functional block is found at the top of the x axis. The contribution of each syndrome to each semantic class is defined by colour-coded dots representing single GO terms within each semantic class (PD: red dots, FTD blue dots and PS: orange dots). The pie charts represent the relative distribution of different semantic classes per functional block for either syndrome. (JPG 228 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_10_of_Stratification_of_candidat... |
Title | Additional file 15: of Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis |
Description | PD-GWAS gene prioritization. Significant SNPs from PD-GWAS and the number of ORFs in LD (from r2 > 0.5 to r2 > 0.8) are shown. Part A contains significant SNPs as per joint analysis, part B contains significant SNPs as per discovery phase. The candidate genes based on proximity are summarized as suggested in the original GWAS. Newly proposed candidate genes within each are identified on the basis of our analysis of the functionally relevant proteins in the PPI network. Genes previously selected by proximity and now also confirmed by functional analysis of the PD-network are in bold font. The top pie chart represents the distribution of proteins across the different relevant processes. In the final column the cell type with major expression (> 5% of average expression) is reported as calculated from the dataset generated by Zhang et al. [13] (A = mature astrocytes, N = neurons, M = microglia, O = oligodendrocytes and, E = endothelial cells). The bottom pie chart represents the distribution of proteins based on cell type expression in human temporal lobe cortex. (JPG 349 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_15_of_Stratification_of_candidat... |
Title | Additional file 15: of Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis |
Description | PD-GWAS gene prioritization. Significant SNPs from PD-GWAS and the number of ORFs in LD (from r2 > 0.5 to r2 > 0.8) are shown. Part A contains significant SNPs as per joint analysis, part B contains significant SNPs as per discovery phase. The candidate genes based on proximity are summarized as suggested in the original GWAS. Newly proposed candidate genes within each are identified on the basis of our analysis of the functionally relevant proteins in the PPI network. Genes previously selected by proximity and now also confirmed by functional analysis of the PD-network are in bold font. The top pie chart represents the distribution of proteins across the different relevant processes. In the final column the cell type with major expression (> 5% of average expression) is reported as calculated from the dataset generated by Zhang et al. [13] (A = mature astrocytes, N = neurons, M = microglia, O = oligodendrocytes and, E = endothelial cells). The bottom pie chart represents the distribution of proteins based on cell type expression in human temporal lobe cortex. (JPG 349 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_15_of_Stratification_of_candidat... |
Title | Additional file 17: of Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis |
Description | Random Distribution. Distribution of the number of matches obtained in 100,000 simulated experiments in which we matched the relevant PD, process-specific, network proteins to randomly generated gene-sets of the same length as the list of ORFs in LD blocks with the top SNPS in the PD-GWAS. The distribution in blue is generated for random gene-sets of the same length as the list of ORFs in LD r2 = 0.5; the distribution in red is generated for random gene-sets of the same length as the list of ORFs in LD r2 = 0.8. (PDF 36 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_17_of_Stratification_of_candidat... |
Title | Additional file 17: of Stratification of candidate genes for Parkinson's disease using weighted protein-protein interaction network analysis |
Description | Random Distribution. Distribution of the number of matches obtained in 100,000 simulated experiments in which we matched the relevant PD, process-specific, network proteins to randomly generated gene-sets of the same length as the list of ORFs in LD blocks with the top SNPS in the PD-GWAS. The distribution in blue is generated for random gene-sets of the same length as the list of ORFs in LD r2 = 0.5; the distribution in red is generated for random gene-sets of the same length as the list of ORFs in LD r2 = 0.8. (PDF 36 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_17_of_Stratification_of_candidat... |
Title | Additional file 17: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | .GO Annotation Frequency. Proteins whose ORF is in the LD blocks around the prioritized SNPs in the PD-GWAS have been evaluate in terms of numbers of GO annotations present in GO for that specific ORF. In red are reported the proteins that correspond to genes that we prioritized with our analysis. In grey, all the other genes are reported. For some of the loci (A) the genes we prioritized was the gene with the maximum number of GO annotations for that locus; in some other cases (B) the genes we prioritized was NOT the gene with the maximum number of GO annotations for that locus. Finally, there are also mixed cases (C). (TIFF 315 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_17_of_Stratification_of_candidat... |
Title | Additional file 18: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | GO Annotation Frequency. Proteins whose ORF is in the LD blocks around the prioritized SNPs in the PD-GWAS have been evaluate in terms of numbers of GO annotations present in GO for that specific ORF. In red are reported the proteins that correspond to genes that we prioritized with our analysis. In grey, all the other genes are reported. For some of the loci (A) the genes we prioritized was the gene with the maximum number of GO annotations for that locus; in some other cases (B) the genes we prioritized was NOT the gene with the maximum number of GO annotations for that locus. Finally, there are also mixed cases (C). (TIFF 315 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_18_of_Stratification_of_candidat... |
Title | Additional file 18: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | GO Annotation Frequency. Proteins whose ORF is in the LD blocks around the prioritized SNPs in the PD-GWAS have been evaluate in terms of numbers of GO annotations present in GO for that specific ORF. In red are reported the proteins that correspond to genes that we prioritized with our analysis. In grey, all the other genes are reported. For some of the loci (A) the genes we prioritized was the gene with the maximum number of GO annotations for that locus; in some other cases (B) the genes we prioritized was NOT the gene with the maximum number of GO annotations for that locus. Finally, there are also mixed cases (C). (TIFF 315 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_18_of_Stratification_of_candidat... |
Title | Additional file 2: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Seeds and Parkinsonian syndromes. (JPG 266 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_2_of_Stratification_of_candidate... |
Title | Additional file 2: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Seeds and Parkinsonian syndromes. (JPG 266 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_2_of_Stratification_of_candidate... |
Title | Additional file 9: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Enrichment Analysis. The biological process-Gene Ontology (BP-GO) terms obtained from the functional enrichment analysis of the entire network (Fig. 1d) were first grouped into semantic classes by semantic similarity and then into functional blocks. More general terms within the same functional blocks are highlighted in grey. Enrichment analysis was then performed for the PD, FTD and PS IIHs separately: enriched semantic classes from these analyses are highlighted in blue for FTD, orange for PS and red for PD. (JPG 790 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_9_of_Stratification_of_candidate... |
Title | Additional file 9: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Enrichment Analysis. The biological process-Gene Ontology (BP-GO) terms obtained from the functional enrichment analysis of the entire network (Fig. 1d) were first grouped into semantic classes by semantic similarity and then into functional blocks. More general terms within the same functional blocks are highlighted in grey. Enrichment analysis was then performed for the PD, FTD and PS IIHs separately: enriched semantic classes from these analyses are highlighted in blue for FTD, orange for PS and red for PD. (JPG 790 kb) |
Type Of Art | Film/Video/Animation |
Year Produced | 2018 |
URL | https://springernature.figshare.com/articles/figure/Additional_file_9_of_Stratification_of_candidate... |
Title | Additional file 11: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Panther enrichment for the entire network. (XLSX 117 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_11_of_Stratification_of_candida... |
Title | Additional file 11: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Panther enrichment for the entire network. (XLSX 117 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_11_of_Stratification_of_candida... |
Title | Additional file 12: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of GO BPs extracted from the g:Profiler enrichment of the entire network and relevant to PD. (XLSX 103 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_12_of_Stratification_of_candida... |
Title | Additional file 12: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of GO BPs extracted from the g:Profiler enrichment of the entire network and relevant to PD. (XLSX 103 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_12_of_Stratification_of_candida... |
Title | Additional file 13: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of PD network proteins responsible for the enrichment of the terms in Supplementary File 6. (XLSX 62 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_13_of_Stratification_of_candida... |
Title | Additional file 13: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of PD network proteins responsible for the enrichment of the terms in Supplementary File 6. (XLSX 62 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_13_of_Stratification_of_candida... |
Title | Additional file 14: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of ORFs in LD with PD-GWAS top SNPs. (XLSX 15 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_14_of_Stratification_of_candida... |
Title | Additional file 14: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | List of ORFs in LD with PD-GWAS top SNPs. (XLSX 15 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_14_of_Stratification_of_candida... |
Title | Additional file 16: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Functions of newly prioritized candidate genes. (XLSX 15 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_16_of_Stratification_of_candida... |
Title | Additional file 16: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | Functions of newly prioritized candidate genes. (XLSX 15 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_16_of_Stratification_of_candida... |
Title | Additional file 5: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the entire network. (XLSX 172 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_5_of_Stratification_of_candidat... |
Title | Additional file 5: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the entire network. (XLSX 172 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_5_of_Stratification_of_candidat... |
Title | Additional file 6: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the FTD IIHs. (XLSX 23 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_6_of_Stratification_of_candidat... |
Title | Additional file 6: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the FTD IIHs. (XLSX 23 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_6_of_Stratification_of_candidat... |
Title | Additional file 7: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the PS IIHs. (XLSX 29 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_7_of_Stratification_of_candidat... |
Title | Additional file 7: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the PS IIHs. (XLSX 29 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_7_of_Stratification_of_candidat... |
Title | Additional file 8: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the PD IIHs. (XLSX 25 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_8_of_Stratification_of_candidat... |
Title | Additional file 8: of Stratification of candidate genes for Parkinsonâ s disease using weighted protein-protein interaction network analysis |
Description | g:Pprofiler enrichment for the PD IIHs. (XLSX 25 kb) |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_8_of_Stratification_of_candidat... |
Title | FBS/BSA media concentration determines CCCP's ability to depolarize mitochondria and activate PINK1-PRKN mitophagy |
Description | Mitochondrial quality control is essential for maintaining a healthy population of mitochondria. Two proteins associated with Parkinson disease, the kinase PINK1 and the E3 ubiquitin ligase PRKN, play a central role in the selective degradation of heavily damaged mitochondria (mitophagy), thus avoiding their toxic accumulation. Most of the knowledge on PINK1-PRKN mitophagy comes from in vitro experiments involving the treatment of mammalian cells with high concentrations of mitochondrial uncouplers, such as CCCP. These chemicals have been shown to mediate off target effects, other than mitochondrial depolarization. A matter of controversy between mitochondrial physiologists and cell biologists is the discrepancy between concentrations of CCCP needed to activate mitophagy (usually >10 µM), when compared to the much lower concentrations used to depolarize mitochondria (<1 µM). Thus, there is an urgent need for optimizing the current methods to assess PINK1-PRKN mitophagy in vitro. In this study, we address the utilization of high CCCP concentrations commonly used to activate mitophagy. Combining live fluorescence microscopy and biochemistry, we show that the FBS/BSA in the cell culture medium reduces the ability of CCCP to induce PINK1 accumulation at depolarized mitochondria, subsequent PRKN recruitment and ubiquitin phosphorylation, and ultimately mitochondrial clearance. As a result, high concentrations of CCCP are required to induce mitophagy in FBS/BSA containing media. These data unite mitochondrial physiology and mitophagy studies and are a first step toward a consensus on optimal experimental conditions for PINK1-PRKN mitophagy and mitochondrial physiology investigations to be carried out in parallel. Abbreviations: BSA: bovine serum albumin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; DMEM: dulbecco's Modified Eagle's Medium; DNP: 2,4-dinitrophenol; FBS: fetal bovine serum; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSH: glutathione; HBSS: Hanks' balanced salt solution; mtKeima: mitochondria-targeted monomeric keima-red; PBS: phosphate buffered saline; PD: Parkinson disease; PINK1: PTEN induced kinase 1; POE SHSY5Ys: FLAG-PRKN over-expressing SHSY5Y cells; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMRM: tetramethylrhodamine methyl ester; WB: western blot; WT: wild-type; ??m: mitochondrial membrane potential |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
URL | https://tandf.figshare.com/articles/FBS_BSA_media_concentration_determines_CCCP_s_ability_to_depolar... |
Title | FBS/BSA media concentration determines CCCP's ability to depolarize mitochondria and activate PINK1-PRKN mitophagy |
Description | Mitochondrial quality control is essential for maintaining a healthy population of mitochondria. Two proteins associated with Parkinson disease, the kinase PINK1 and the E3 ubiquitin ligase PRKN, play a central role in the selective degradation of heavily damaged mitochondria (mitophagy), thus avoiding their toxic accumulation. Most of the knowledge on PINK1-PRKN mitophagy comes from in vitro experiments involving the treatment of mammalian cells with high concentrations of mitochondrial uncouplers, such as CCCP. These chemicals have been shown to mediate off target effects, other than mitochondrial depolarization. A matter of controversy between mitochondrial physiologists and cell biologists is the discrepancy between concentrations of CCCP needed to activate mitophagy (usually >10 µM), when compared to the much lower concentrations used to depolarize mitochondria (<1 µM). Thus, there is an urgent need for optimizing the current methods to assess PINK1-PRKN mitophagy in vitro. In this study, we address the utilization of high CCCP concentrations commonly used to activate mitophagy. Combining live fluorescence microscopy and biochemistry, we show that the FBS/BSA in the cell culture medium reduces the ability of CCCP to induce PINK1 accumulation at depolarized mitochondria, subsequent PRKN recruitment and ubiquitin phosphorylation, and ultimately mitochondrial clearance. As a result, high concentrations of CCCP are required to induce mitophagy in FBS/BSA containing media. These data unite mitochondrial physiology and mitophagy studies and are a first step toward a consensus on optimal experimental conditions for PINK1-PRKN mitophagy and mitochondrial physiology investigations to be carried out in parallel. Abbreviations: BSA: bovine serum albumin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; DMEM: dulbecco's Modified Eagle's Medium; DNP: 2,4-dinitrophenol; FBS: fetal bovine serum; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSH: glutathione; HBSS: Hanks' balanced salt solution; mtKeima: mitochondria-targeted monomeric keima-red; PBS: phosphate buffered saline; PD: Parkinson disease; PINK1: PTEN induced kinase 1; POE SHSY5Ys: FLAG-PRKN over-expressing SHSY5Y cells; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMRM: tetramethylrhodamine methyl ester; WB: western blot; WT: wild-type; ??m: mitochondrial membrane potential |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
URL | https://tandf.figshare.com/articles/FBS_BSA_media_concentration_determines_CCCP_s_ability_to_depolar... |
Title | FBS/BSA media concentration determines CCCP's ability to depolarize mitochondria and activate PINK1-PRKN mitophagy |
Description | Mitochondrial quality control is essential for maintaining a healthy population of mitochondria. Two proteins associated with Parkinson disease, the kinase PINK1 and the E3 ubiquitin ligase PRKN, play a central role in the selective degradation of heavily damaged mitochondria (mitophagy), thus avoiding their toxic accumulation. Most of the knowledge on PINK1-PRKN mitophagy comes from in vitro experiments involving the treatment of mammalian cells with high concentrations of mitochondrial uncouplers, such as CCCP. These chemicals have been shown to mediate off target effects, other than mitochondrial depolarization. A matter of controversy between mitochondrial physiologists and cell biologists is the discrepancy between concentrations of CCCP needed to activate mitophagy (usually >10 µM), when compared to the much lower concentrations used to depolarize mitochondria (<1 µM). Thus, there is an urgent need for optimizing the current methods to assess PINK1-PRKN mitophagy in vitro. In this study, we address the utilization of high CCCP concentrations commonly used to activate mitophagy. Combining live fluorescence microscopy and biochemistry, we show that the FBS/BSA in the cell culture medium reduces the ability of CCCP to induce PINK1 accumulation at depolarized mitochondria, subsequent PRKN recruitment and ubiquitin phosphorylation, and ultimately mitochondrial clearance. As a result, high concentrations of CCCP are required to induce mitophagy in FBS/BSA containing media. These data unite mitochondrial physiology and mitophagy studies and are a first step toward a consensus on optimal experimental conditions for PINK1-PRKN mitophagy and mitochondrial physiology investigations to be carried out in parallel. Abbreviations: BSA: bovine serum albumin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; DMEM: dulbecco's Modified Eagle's Medium; DNP: 2,4-dinitrophenol; FBS: fetal bovine serum; FCCP: carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSH: glutathione; HBSS: Hanks' balanced salt solution; mtKeima: mitochondria-targeted monomeric keima-red; PBS: phosphate buffered saline; PD: Parkinson disease; PINK1: PTEN induced kinase 1; POE SHSY5Ys: FLAG-PRKN over-expressing SHSY5Y cells; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TMRM: tetramethylrhodamine methyl ester; WB: western blot; WT: wild-type; ??m: mitochondrial membrane potential |
Type Of Material | Database/Collection of data |
Year Produced | 2019 |
Provided To Others? | Yes |
URL | https://tandf.figshare.com/articles/FBS_BSA_media_concentration_determines_CCCP_s_ability_to_depolar... |
Title | protein interaction network online tool (PINOT) |
Description | The PINOT web server takes, as input, a text file containing a simple list of HGNC approved symbols. The genes within the list are the "seeds" to extract protein-protein interactions (PPIs) from 7 databases within the IMEx consortium (Biogrid, Intact, Mint, InnateDB, bhf-UCL, MBinfo and Uniprot). PPIs are downloaded from PSICQUIC using an API protocol embedded within the R package "psicquic" [Shannon P (2018). PSICQUIC Common QUery InterfaCe. R package version 1.18.0.]. Downloaded files are then parsed in order to merge the information collected from different databases. Each annotation undergoes quality control steps to remove poor annotations. Each annotation is then scored based on the number of different publications and interaction detection methods used for the identification. PINOT output contains all scored interactions for the genes included in the input list. The text file is visualized on the webpage and can be downloaded, in addition the file can be emailed to the user if they consent to providing an email address. |
Type Of Material | Data handling & control |
Year Produced | 2018 |
Provided To Others? | No |
Impact | PINOT is the development of the method called weighted protein-protein interaction network analysis (WPPINA) that has been published in: PMID:28004582 (Journal of Proteomics Research, 16:999-1013, 2017); PMID:29898659 (BMC genomics, 19:452, 2018) and used in the research presented in: PMID:29513927 (Proteomics, 18:e1700444, 2018); PMID:29794074 (Cancer Research, 78:3731-3739, 2018) and PMID:30283816 (Neurology Genetics, 4:e266, 2018). The website runs in a beta version and we foresee to release it to the general public upon publication in 2019. |
URL | http://www.reading.ac.uk/bioinf/PINOT/PINOT_form.html |
Description | The International Parkinson Disease Genomics Consortium |
Organisation | German Centre for Neurodegenerative Diseases |
Country | Germany |
Sector | Public |
PI Contribution | This is a hugem consortium. WE are founder members. WE help manage the consortium, we obtain grant funds for it and we contribute patient samples and data |
Collaborator Contribution | They contribute in the same way we do |
Impact | Huge number of publications: too many to list. Genetics, Gene expression and Neurology |
Start Year | 2007 |
Description | The International Parkinson Disease Genomics Consortium |
Organisation | Pitié-Salpêtrière Hospital |
Country | France |
Sector | Hospitals |
PI Contribution | This is a hugem consortium. WE are founder members. WE help manage the consortium, we obtain grant funds for it and we contribute patient samples and data |
Collaborator Contribution | They contribute in the same way we do |
Impact | Huge number of publications: too many to list. Genetics, Gene expression and Neurology |
Start Year | 2007 |
Description | Whole genome analyses of neurologic diseases |
Organisation | National Institutes of Health (NIH) |
Country | United States |
Sector | Public |
PI Contribution | many neurologic disease whole genome associations including Alzheimer's disease, parkinson's disease, stroke, progressive supranuclear palsy, motor neuron disease |
Collaborator Contribution | Joint students have worked on these projects |
Impact | In each diseaase, we (as part of international consortia) have found risk factor loci which have eiother now been published or are in the publication process |
Start Year | 2007 |
Description | Whole genome expression database |
Organisation | National Institute on Aging |
Department | Laboratory of Neurogenetics |
Country | United States |
Sector | Public |
PI Contribution | We are just abouhttp://bit.ly/braineac (ignore certificate warning) username: UKBEC password: BraineacNOW t to relase this database to the general public |
Collaborator Contribution | We worked with our Us collaborators on this project (Singleton/Cookson): about half the work each |
Impact | Just search Ryten plus Singleton on pubmed These are the current PMID 23223016, 23177596, 22892372 , 22777693, 22723018, 22433082, 21738488 , 21292315 |
Start Year | 2009 |
Description | "Alpha-synuclein & Parkinson's disease Conference: lessons from the past 20 years" Barcelona |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker to The University of Barcelona Medical School - Talk title: "Genetics of synucleinopathies" |
Year(s) Of Engagement Activity | 2017 |
Description | "Do Genetic Findings Converge on Discrete Pathophysiological Pathways?" invited lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 12th National Alzheimer Disease Conference, Virtual Eskisehir Turkey |
Year(s) Of Engagement Activity | 2022 |
Description | "Genomics in Neurodegenerative disease -- what are we up to" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture as HKUST IAS fellow, Hong Kong |
Year(s) Of Engagement Activity | 2019 |
Description | "Neurogenetic Foundations of Movement Disorders - The Key to Cure?" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Keynote Lecture |
Year(s) Of Engagement Activity | 2019 |
Description | "The Genetics of the Dementias" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Invited teaching lecture at Queen Square on MSc Human Genetics course 2018-19 |
Year(s) Of Engagement Activity | 2019 |
Description | 06/07/23 The role of genetics in the pathophysiology of PD 6th World Parkinson Congress in Barcelona On behalf of the Program Committee Invited Speaker |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 06/07/23 The role of genetics in the pathophysiology of PD 6th World Parkinson Congress in Barcelona On behalf of the Program Committee Roundtable Host. |
Year(s) Of Engagement Activity | 2023 |
URL | https://wpc2023.org/page/ScientificProgram |
Description | 06/09/23 Invited Keynote speaker Leeds ARUK Network symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 06/09/23 Alzheimer's. From genetic analysis to treatment - KEYNOTE Leeds ARUK Network symposium Profs Anthony Turner and Renee Frank Invited Keynote speaker |
Year(s) Of Engagement Activity | 2023 |
Description | 09/11/23 IAS Distinguished Lecture: The Genetics of the Major Neurodegenerative Diseases: From Mechanisms to Treatments |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 09/11/23 IAS Distinguished Lecture: The Genetics of the Major Neurodegenerative Diseases: From Mechanisms to Treatments HKUST Jockey Club Institute for Advanced Study Hong Kong Invited Speaker |
Year(s) Of Engagement Activity | 2023 |
Description | 13/10/23 "Genetics of Alzheimer's Disease: its convergence on and divergence from amyloid hypothesis" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 13/10/23 "Genetics of Alzheimer's Disease: its convergence on and divergence from amyloid hypothesis" 13th National Alzheimer's Congress - Bodrum, Turkey Invitation Murat Emre And Bedia Samanci Behavioral Neurology and Movement Disorders Unit Istanbul Faculty of Medicine, Istanbul University Invited Opening Lecture |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.bing.com/videos/search?q=13th+National+Alzheimer%27s+Congress+%e2%80%93+Bodrum%2c+Turkey... |
Description | 15/09/23 Honorary doctorate seminar University of Rijeka, Croatia |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 15/09/23 Honorary doctorate seminar University of Rijeka, Croatia On behalf of the University of Rijeka Madam Rector, Prof. Snježana Prijic-Samaržija, Ph.D. |
Year(s) Of Engagement Activity | 2023 |
Description | 16/05/23 Virtual for Biomarkers Course Invited speaker Teaching |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | invited teaching talk by Romina Garrido on behalf of Mark Calvet Barcelona Beta Brain Research Center (BBRC) Virtual for Biomarkers Course. |
Year(s) Of Engagement Activity | 2023 |
Description | 2017 EMBO conference on "Mechanisms of Neurodegeneration" at the EMBL Advanced Training Centre (ATC) in Heidelberg |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Talk at EMO - Genomics of Neurodegeneration |
Year(s) Of Engagement Activity | 2017 |
Description | 2018 Parkinson's UK conference York |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Invited Keynote speaker |
Year(s) Of Engagement Activity | 2018 |
Description | 2nd Regional DBS meeting - 'Deep brain stimulation: New Horizons in Neurology and Psychiatry' Westin Zagreb hotel. Zagreb, Croatia |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker - talk: Genomic analysis of neurological diseases and possible implications on society |
Year(s) Of Engagement Activity | 2017 |
Description | 2nd international Taiwanese Congress of Neurology and 2017 Annual meeting of Taiwan Neurological Society |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker - Talk title: Current Advance in Genetic Understanding of Parkinson's Disease |
Year(s) Of Engagement Activity | 2017 |
Description | 30/10/23 Enhancing Basic Clinical Collaborative Research Engagement for Health and Well-Being |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 30/10/23 Enhancing Basic Clinical Collaborative Research Engagement for Health and Well-Being Plenary Speaker for 10th Faculty of Basic Medical Sciences Annual Scientific Conference - Nigeria - Virtual Invited by Prof AJ Akindele University of Lagos, Nigeria Invited lecture |
Year(s) Of Engagement Activity | 2023 |
Description | 31/10/23 Brain Health and the Latest Research into Dementia Prevention Dementia Summit |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 31/10/23 Brain Health and the Latest Research into Dementia Prevention Dementia Summit, The King's Fund - No. 11 Cavendish Square, London W1G 0AN Invited speaker |
Year(s) Of Engagement Activity | 2023 |
Description | A tribute to Stuart - talk about him as a person, colleague, and contributor to dementia research |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | The Alzheimer's Research UK Conference Brighton Centre, Kings Road, Brighton BN1 2GR invited to speak in a session in memory of Stuart Pickering-Brown |
Year(s) Of Engagement Activity | 2022 |
Description | AD research and future interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Virtual Interview Yasemin Saplakoglu Biology Staff Writer Quanta Magazine C: (347) 585-9167 New York, New York |
Year(s) Of Engagement Activity | 2022 |
Description | Advances in Alzheimer's Disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker - The 10th Xiangya International Symposium of the Clinical and Basic Research on Neurodegenerative Disorders, China |
Year(s) Of Engagement Activity | 2019 |
Description | Alzheimer's disease pathogenesis: what do we know and why have clinical trials failed |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Invited public lecture |
Year(s) Of Engagement Activity | 2019 |
Description | Amyloid hypoithesis.. what was right and what was wrong Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | 6th Rijeka Forum on Neurodegenerative Disease Croatian Academy of Sciences and Arts Department of Biomedical Sciences in Rijeka |
Year(s) Of Engagement Activity | 2022 |
URL | https://neurolab.uniri.hr/?page_id=24#:~:text=The%206th%20Rijeka%20Forum%20of,of%20the%20amyloid%20c... |
Description | Aß hypothesis, AD genetics" |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited lecture - Wenner-Gren Center (Sveavägen 166), Stockholm, Sweden symposium : "Amyloid diseases: from biochemistry to clinical applications" |
Year(s) Of Engagement Activity | 2019 |
Description | Crispr Talk - John and Selina |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Lecture Royal London Hospital |
Year(s) Of Engagement Activity | 2019 |
Description | Dementias - Invited Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | https://www.fondazioneprada.org/project/human-brains-preserving-the-brain/?lang=en#:~:text=Realized%20in%20collaboration%20with%20thirteen,2022)%20at%20Fondazione%20Prada's%20Milan invited Lecture |
Year(s) Of Engagement Activity | 2022 |
Description | Dementias - Invited Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | "Preserving the Brain" is a forum on neurodegenerative diseases presented in September and October 2022, as the fourth phase of "Human Brains," Fondazione Prada's neuroscience project. Realized in collaboration with thirteen of the most prestigious international neuroscience institutes and universities, "Human Brains: Preserving the Brain - Forum on Neurodegenerative Diseases" comprises an exhibition (16 September - 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises and online. "Preserving the Brain" aims to stimulate an open and critical exchange between international scientists and experts on neurodegenerative diseases, such as Alzheimer's, Parkinson's, Amyotrophic lateral sclerosis and Multiple sclerosis, which are widely spread and as yet incurable. The forum participants include researchers, patient associations, and representatives of health care institutions and the pharmaceutical and biotechnology industries. They will debate the current state of knowledge of these diseases and the tools currently used to fight them, while also seeking to identify lacunae in the search for possible therapies, and jointly defining priorities and strategies to sustain scientific research. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.fondazioneprada.org/project/human-brains-preserving-the-brain/?lang=en#:~:text=Realized%... |
Description | Department of Pharmacology, Mansfield Road, Oxford |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Pharmacology, Anatomical Neuropharmacology and Drug Discovery Seminars - Talk title: Genomics of neurodegenerative diseases |
Year(s) Of Engagement Activity | 2018 |
Description | Epidemiology of Alzheimer's Disease and Related Disorders |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Keynote speaker on teaching course at Bordeaux School of Neuroscience |
Year(s) Of Engagement Activity | 2019 |
Description | Faculty of Medicine, University of Iceland Vatnsmyrarvegur 16 101 Reykjavik - Iceland |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Distinguished speakers series |
Year(s) Of Engagement Activity | 2017 |
Description | Failures in Damage Response Underlie Late Onset Neurodegenerative Diseases and Explain the Relationship Between Pathology and Genetics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Virtual UK-Russia online forum on Neurodegenerative Diseases and Brain Plasticity Requested by Alena Gureva | Science and Innovation Officer, UK Science & Innovation Network in Russia British Embassy Moscow | Smolenskaya Naberezhnaya, 10 | Moscow 121099 |
Year(s) Of Engagement Activity | 2022 |
Description | Fifth Alzheimer's Research UK Oxford Drug Discovery Institute Collaborators' Meeting. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Talking at oxford DDI Collaborators meeting |
Year(s) Of Engagement Activity | 2018 |
Description | Genetic Analysis of Neurodegeneration Implicates a Failure of Damage Response Pathways Pre-recorded and live Q&A |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Neural Pathways Underlying Brain Function and Pathologies Organized by: Nature Portfolio, Chinese Institute for Brain Research, Beijing (CIBR) Supported by: Beijing Municipal Science & Technology Commission, Administrative Committee of Zhongguancun This event aims to bring together Chinese and international researchers at the forefront of brain science to share their recent achievements in helping to push our understanding forward under both normal and pathological conditions. |
Year(s) Of Engagement Activity | 2022 |
URL | https://neuralpathways.natureresearch.cn/ |
Description | Genetic analysis of late onset degenerative diseases implicates failures of damage response |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Speaker invitation and Announcement of The Brain Prize Awardee 2019 Copenhagen, Denmark |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Supporters |
Results and Impact | Invited Lecture Weston's meeting - 50th Year Anniversary Symposium, 33 Queen Square |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Lecture - Wolfson Institute for Biomedical Research (WIBR) mini-symposium - Sainsbury Wellcome Centre London |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Supporters |
Results and Impact | Wolfson final symposium - Institute of Child Health London |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics and neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Invited to present a teaching lecture to the Basal Ganglia Club Gilliatt Lecture Theatre Queen Square by Dr Amit Batla MBBS, MA (Clin Ed), MD (Med), DM (Neurology), FRCP Clinical Associate Professor (teaching), Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology |
Year(s) Of Engagement Activity | 2022 |
Description | Genetics in neurodegenerative disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited lecture at 2019 International Conference of Korean Dementia Association, (IC-KDA 2019) Seoul |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics in neurodegenerative diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Invited teaching to PhD students on Biomarkers for neurodegenerative diseases PhD course |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics in neurodegenerative diseases - teaching lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | "Biomarkers for neurodegenerative diseases" Day 1 - London edition PhD course "Biomarkers for neurodegenerative diseases" - 2022 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.ucl.ac.uk/ion/study/biomarkers-neurodegenerative-diseases |
Description | Genetics of Alzheimer's |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited lecture at Hong Kong University of Science and Technology ShenZhen branch |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics of Alzheimer's and other neuro-degenerative disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture - China National Genebank - Jinsha Road, Dapeng New District, Shenzhen |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics of Dementias |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Lecture XXIV World Congress of Neurology, Dubai - AE |
Year(s) Of Engagement Activity | 2019 |
Description | Genetics of Neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture at Lisbon AD/PD meeting |
Year(s) Of Engagement Activity | 2019 |
Description | Genomic Analysis of Neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Zoom Teaching lecture - invited by Dr Kerri Kinghorn ucl lectures Neurological diseases module GENE003 |
Year(s) Of Engagement Activity | 2022 |
Description | Genomic analysis of neurodegenerative diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Invited lecture Scientific Talk (to senior scientists) Odense University Hospital, Denmark |
Year(s) Of Engagement Activity | 2019 |
Description | Genomic analysis of the mechanisms of neurodegenerative disease in Denmark to PhD students |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Teaching Lecture to PhD students in neuroscience at the NeuroGrad Winter School, Copenhagen |
Year(s) Of Engagement Activity | 2019 |
URL | https://neurograd.ku.dk/neurograd-winter-school/ |
Description | Genomic clues to neurodegenerative disease mechanisms |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Brain Prize Special Lecture/ keynote lecture at ECNP Congress in Copenhagen |
Year(s) Of Engagement Activity | 2019 |
Description | Genomics of Neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited lecture - 3rd Rijeka Forum on Neurodegenerative diseases, Croatia Rijeka |
Year(s) Of Engagement Activity | 2019 |
Description | Genomics of neurodegenerative disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Keynote speaker FENS The Serbian Neuroscience Society. with the Neuroscience societies of Romania and Turkey. Belgrade Serbia. |
Year(s) Of Engagement Activity | 2019 |
Description | Grand Rounds Invitation: Albert Einstein College of Medicine - Montefiore Medical Center |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Grand Rounds Invitation: Albert Einstein College of Medicine - Montefiore Medical Center talk entitled: Genomic analysis of neurodegenerative diseases implicates failures of damage clearance with Q&A |
Year(s) Of Engagement Activity | 2021 |
Description | Hong Kong Student Association of Neuroscience (HKSAN) - Neuroscience: Past, Present, Future Symposium of 1st Asia-Pacific Neuroscience Student Congress and HKSAN 2nd Annual Conference (APNSC-HKSAN) 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker to Hong Kong Student Association of Neuroscience (HKSAN) - Neuroscience: Past, Present, Future Symposium of 1st Asia-Pacific Neuroscience Student Congress and HKSAN 2nd Annual Conference (APNSC-HKSAN) 2021. Talk entitled: Whole genome analysis of neurodegeneration |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.hksaneuroscience.org/apnsc-hksan-programme |
Description | INTERVIEW with- Camilla De Fazio - Popular Science about the FDA approval of the first new drug for Alzheimer's disease - |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | INTERVIEW with- Camilla De Fazio - Popular Science about the FDA approval of the first new drug for Alzheimer's disease |
Year(s) Of Engagement Activity | 2021 |
URL | http://www.popsci.it/approvazione-di-aducanumab-contro-lalzheimer-una-svolta-tra-molte-incertezze.ht... |
Description | ISMND Science Webinar Series |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Supporters |
Results and Impact | Invited speaker by Diane Bovenkamp, Ph.D. Vice President, Scientific Affairs, BrightFocus Foundation Genomic analysis of neurodegenerative disease reveals commonalities between them and point the way towards therapies |
Year(s) Of Engagement Activity | 2023 |
Description | Inaugural Baillieu Myer Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Inaugural Baillieu Myer Lecture, in honour of contribution to medical research, in particular dementia research |
Year(s) Of Engagement Activity | 2019 |
Description | Interview with USA Today Health Reporter Ken Alltucker |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Interview with USA Today Health Reporter Ken Alltucker about results of new Alzheimer drug trials |
Year(s) Of Engagement Activity | 2022 |
Description | Invited Interview for YouTube Channel |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Recording for the Wonderbirds show - Filmed interview |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.youtube.com/watch?v=1Mp1E4pYE2k |
Description | Invited Interview with the Daily Mail Newspaper for new Alzheimer drugs |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 11/05/23 Daily Mail's Good Health supplement on the newer drugs for Alzheimer's Zoom recording with the Daily Mail Jo Waters Daily Mail Invited Interview |
Year(s) Of Engagement Activity | 2023 |
Description | Invited Interview with the Financial Times |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 09/06/23 Lecanemab Interview Financial Times story Hannah Kuchler Global Pharmaceuticals Correspondent Financial Times Invited Interview |
Year(s) Of Engagement Activity | 2023 |
Description | Invited Interview/Q&A - Biomarkers for neurodegenerative diseases |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Cars and Scientists short film series, now supported by Jackie Stewart's charity Race Against Dementia |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.raceagainstdementia.com/research/accelerating-research/ |
Description | Invited Keynote speaker - Genomic analyses of neurodegenerative diseases for Genomics of Brain Disorders 2023 - Wellcome Genome Campus, near Cambridge, UK |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | 19/05/23 Genomic analyses of neurodegenerative diseases Genomics of Brain Disorders 2023 - Wellcome Genome Campus, near Cambridge, UK Invited Keynote speaker On behalf of the Scientific Programme Committee: • Cornelis Blauwendraat NIH/National Institute on Aging, USA • Kristen Brennand Yale University, USA • Anders Børglum Aarhus University, Denmark • Mina Ryten UCL Great Ormond Street Institute of Child Health, UK Keynote speaker Teaching |
Year(s) Of Engagement Activity | 2023 |
Description | Invited Lecture - Zoom - 10. National Alzheimer Congress, Turkey |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | invited lecture at 10th National Alzheimer Congress, Turkey -Recent Advances in the Genetics of Alzheimer's Disease - Chairpersons: Murat Emre, Hasmet Hanagasi To increase awareness of latest research |
Year(s) Of Engagement Activity | 2020 |
Description | Invited Lecture - Zoom - NeuroUpdate Kolkata |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture - Genetics of Neurodegeneration for Atanu Biswas M.D., D.M.(Neurology),Professor Department of Neurology Institute of Postgraduate Medical Education & Research and Bangur Institute of Neurosciences Kolkata - 700 025, India to increase awareness of latest research. |
Year(s) Of Engagement Activity | 2020 |
Description | Invited Lecture - Zoom - Seminar for Moscow Science Festival |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | invited lecture for Viola Egikova, Deputy Director, Institute for Advanced Brain Studies, Moscow State University and Tatiana Iakovleva Head, UK Science and Innovation Network in Russia British Embassy to increase awareness |
Year(s) Of Engagement Activity | 2020 |
Description | Invited Plenary Lecture for ABN meeting in Belfast |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 10/05/23 "The Genetics of Neurodegenerative Disease" ABN (Belfast) Invited by ABN meetings secretary PLENARY LECTURE |
Year(s) Of Engagement Activity | 2023 |
Description | Invited Round table public talk |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Invited public round table - Brain Prize Evening - Lundbeck - BNA Festival, The Convention Centre Dublin |
Year(s) Of Engagement Activity | 2019 |
Description | Invited Speaker - 5th RIJEKA FORUM ON NEURODEGENERATIVE DISEASES NEURODEGENERATIVE DISEASES: TOWARD THERAPY |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker to 5th RIJEKA FORUM ON NEURODEGENERATIVE DISEASES NEURODEGENERATIVE DISEASES: TOWARD THERAPY Talk entitled: Genetic analysis of decline of disease rate |
Year(s) Of Engagement Activity | 2021 |
URL | https://uniri.hr/wp-content/uploads/2021/11/Simpozij-49_finalno.pdf |
Description | Invited Speaker 30th Adler Symposium on Alzheimer's Disease |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Supporters |
Results and Impact | Goal of the Symposium The 30th anniversary Adler Symposium will focus on issues that are directly relevant to Alzheimer's disease (AD) or on therapies for other disorders that may impact AD. There are four major themes: 1) AD diagnostics and therapeutics; 2) Non-AD therapies that could impact our thinking about AD; 3) Role of genetics, epigenetics, and innate immunity in AD; 4) Brain cell senescence and systemic factors that influence neurodegeneration. The overall format of the meeting should also provide plentiful opportunities for informal interchanges among all the speakers and participants. |
Year(s) Of Engagement Activity | 2023 |
Description | Invited interview for BBC Radio 4 Today programme interview with VICTORIA GARDINER Senior Journalist on new Alzheimer drugs |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | BBC Radio 4 Today programme invited interview with VICTORIA GARDINER Senior Journalist for new Alzheimer drugs |
Year(s) Of Engagement Activity | 2023 |
Description | Invited lecture - Alector Seminar and round table |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Invited speaker entitled: Genomic analysis of neurodegeneration implicates proteostasis as the key problem in late-onset disease followed by round-table discussions |
Year(s) Of Engagement Activity | 2021 |
Description | Invited speaker - The Genetics Society of Korea |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Invited Plenary Speaker to The Genetics Society of Korea |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.illumina.com/content/illumina-marketing/spac/en_AU/events/conferences/2021/icgsk-2021.ht... |
Description | Invited speaker NIH Clinical Neuroscience Grand Rounds Main Lecture Speaker |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker talk entitled: Genomic Analysis of the Major Neurodegenerative Diseases - NIH Clinical Neuroscience Grand Rounds with Q&A |
Year(s) Of Engagement Activity | 2021 |
Description | Invited speaker to 45th FEBS Congress |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Talk entitled: Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk at 45th FEBS conference |
Year(s) Of Engagement Activity | 2021 |
URL | https://2021.febscongress.org/ |
Description | Invited speaker to The 15th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) Eisai-sponsored Satellite symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Talk entitled:The biological and genetic evidence of the Aß pathway The 15th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) Eisai-sponsored Satellite symposium |
Year(s) Of Engagement Activity | 2021 |
URL | https://adpd2021.kenes.com/ |
Description | Invited talk to the Elderly |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Invited speaker at Chinese Dementia Meeting at Community Elder Center at Hebei, China |
Year(s) Of Engagement Activity | 2019 |
Description | James Parkinson Memorial, The London - Bearsted Lecture Theatre |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Genetics of Parkinsonism |
Year(s) Of Engagement Activity | 2017 |
Description | Keynote Lecture - Genomics of Neurodegeneration: On the way to therapies |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 13/06/23 Keynote Lecture - Genomics of Neurodegeneration: On the way to therapies IOE, UCL's Faculty of Education and Society, 20 Bedford Way, Bloomsbury, WC1 Invitation from UCL Professors Trevor Smart and Antonella Riccio UCL 14th edition Neuroscience Symposium - keynote speaker bringing together over 800 Neuroscientists, policy and industry attendees. Delegates have the chance to create new cross-disciplinary links, foster collaboration between basic and clinical researchers and visit our trade exhibition |
Year(s) Of Engagement Activity | 2023 |
Description | Keynote Presentation Molecular Neurodegeneration and Therapeutic Approaches course: Genomic analysis of neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Keynote Presentation Molecular Neurodegeneration and Therapeutic Approaches course - Genomic analysis of neurodegeneration Wellcome Genome Campus in person Hinxton, Cambridgeshire |
Year(s) Of Engagement Activity | 2022 |
URL | https://coursesandconferences.wellcomeconnectingscience.org/event/molecular-neurodegeneration-and-th... |
Description | Meet the Professors |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Round table public talk |
Year(s) Of Engagement Activity | 2019 |
Description | Multiple Media Interviews on latest drug release for Alzheimer's. |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 17/07/23 Interviews following the announcement of the results of the drug trials on Donanemab whilst at the AAIC meeting in Amsterdam. AAIC Conference Amsterdam 1. BBC TV news 2. BBC Today Radio 3. BBC Radio Wales 4. Radio Scotland 5. Radio Northern Ireland SEPARATE INTERVIEWS WITH JOURNALISTS Public Engagement |
Year(s) Of Engagement Activity | 2023 |
Description | Neanderthals - talk for The National Trust |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Lecture in response to a request to talk to a regional National Trust membership |
Year(s) Of Engagement Activity | 2019 |
Description | New Scientist Invited Interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | 22/05/23 The future of Alzheimer's treatments Interview for feature sponsored by Eisai Michael Brooks - New Scientist Invited Interview |
Year(s) Of Engagement Activity | 2023 |
Description | Opening lecture: Alzheimer's disease: a personal view on early diagnosis and treatment |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture - XVIII Teófilo Hernando's International Summer School of Pharmacology Frontier Biomarkers and Drug Discovery for the Early Diagnosis and Treatment of Alzheimer's Disease |
Year(s) Of Engagement Activity | 2019 |
Description | Pan-London regional teaching day for all the neurology registrars in London |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Pan-London regional teaching day for all the neurology registrars in London - talk - Genomics and neurology |
Year(s) Of Engagement Activity | 2017 |
Description | Parkinson's Disease Gordon Research Conference. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Parkinson's Disease Genetics and Systems Biology- Discussion Leader |
Year(s) Of Engagement Activity | 2017 |
Description | Pre-congress Course I - Advances in Research, Science & Treatment - Teaching |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 04/07/23 Pre-symptomatic genetic testing in predicting PD 6th World Parkinson Congress in Barcelona Invitation On behalf of the Program Committee Pre-congress Course I - Advances in Research, Science & Treatment - Teaching |
Year(s) Of Engagement Activity | 2023 |
URL | https://wpc2023.org/page/AboutCongress |
Description | Progress in the genomic analysis of neurodegeneration |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Lecture to the department of Neurodegenerative Disease as an update on work in progress |
Year(s) Of Engagement Activity | 2019 |
Description | Rethinking PD: From a Single Disease to Multiple Diseases:: Genetics, Epigenetics and Environmental Factors |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture by The Preuss Foundation Seminar on State of the Art Parkinson's Disease Research ~ La Jolla, California |
Year(s) Of Engagement Activity | 2019 |
Description | Second Duesseldorf-Juelich Symposium on Neurodegenerative Diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Genomics and aetiology of Parkinson's Disease |
Year(s) Of Engagement Activity | 2017 |
Description | Session 4 - Panel discussion: 'The Future of Neuroscience' |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture - UCL Neuroscience Symposium 10th Anniversary, UCL Institute of Education |
Year(s) Of Engagement Activity | 2019 |
Description | Skype 2 hour lecture to students |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Teaching Lecture to Masters Students "Athens International Master's Programme in Neurosciences" University of Athens Department of Biology |
Year(s) Of Engagement Activity | 2019 |
Description | Stanford University - Brain Rejuvenation Mini-symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker Stanford University - Brain Rejuvenation Mini-symposium |
Year(s) Of Engagement Activity | 2018 |
Description | Talk at CITERSoc December Workshop Cardiff |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker - Talk title: "Tissue engineering to Combat Ageing Diseases" |
Year(s) Of Engagement Activity | 2018 |
Description | Talk to Grand Rounds at Royal London Hospital |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Talk entitled: Genomic analysis suggests failing damage responses underlie diseases to the Grand Rounds of the Royal London Hospital |
Year(s) Of Engagement Activity | 2021 |
Description | Tau 2020 Conference in Washington |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invitation to Present latest updates at Tau 2020 - On behalf of the Alzheimer's Association, the Rainwater Foundation, and CurePSP to move Tau research forward |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.alz.org/tau2020/overview.asp |
Description | Teaching Lecture - PhD course "Biomarkers for neurodegenerative diseases" - 2021 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited teaching lecture entitled: Genetics in neurodegenerative diseases with Q&A afterwards |
Year(s) Of Engagement Activity | 2021 |
Description | Teaching lecture UCL |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Genetics of Neurological diseases module GENE003 UCL |
Year(s) Of Engagement Activity | 2021 |
Description | Teaching lecture UCL - The importance of genetics and molecular biology in neurodegenerative diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Teaching lecture - for the Clinical Neuroscience MSc 33 QS Lecture Theatre |
Year(s) Of Engagement Activity | 2022 |
Description | The 12th World Congress on Controversies in Neurology (CONy), Warsaw, Poland |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited speaker - Talk title: PD associated with lysosome dysfunction and PD associated with mitochondrial dysfunction are different diseases. |
Year(s) Of Engagement Activity | 2018 |
Description | The importance of genetics and molecular biology in neurodegenerative diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Invited teaching UCL - Basic neuroscience and investigation of Nervous system - CLNE0009 Queen Square |
Year(s) Of Engagement Activity | 2019 |
Description | The importance of genetics and molecular biology in neurodegenerative diseases |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Invitation to Lecture on MRes Translational Neuroscience programme - 7 Queen Square |
Year(s) Of Engagement Activity | 2019 |
Description | The role of genetics and genetic testing in PD |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Lecture at World Parkinson Coalition 2019 Kyoto, Japan |
Year(s) Of Engagement Activity | 2019 |
Description | University Menéndez Pelayo, in the course XVI International School of Pharmacology < |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Teaching session - Understanding Brain Diseases - Alzheimer's Disease |
Year(s) Of Engagement Activity | 2017 |
Description | Visit to Columbia University New York |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Advances in Precision Medicine: Genetics - Dr Hardy focuses on the genetic analysis of complex traits related to neurological disease, and in population genetics to understand the underlying genetics of a disorder so he can work with those making cellular and animal models of the disease to help, both in the understanding of disease mechanisms and to help in the search for treatments |
Year(s) Of Engagement Activity | 2017 |
Description | Webinar Lecture across Qatae and Oman |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The audience will be quite mixed, including students, clinicians (neurologists, geriatric psychiatrists, geriatricians), researchers across Qatar and Oman. Lecture for DRI on progress so far, challenges and future directions for dementia research |
Year(s) Of Engagement Activity | 2020 |
Description | Webinar Series Lecture Neuroscience in Africa |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The Genetics of Parkinson's Disease: Understanding the Differences between European & African Populations. to raise awareness in Africa |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.youtube.com/watch?v=Lf6woi9zKCs |
Description | What is the relationship between mendelian disease and sporadic disease (and how does the environment fit in?) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Third UCL Queen Square Motor Neuron Disease Centre International Symposium Lecture Theatre, 33 QS Invited KEYNOYE Speaker |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.ucl.ac.uk/ion/events/2022/sep/third-ucl-queen-square-motor-neuron-disease-centre-virtual... |
Description | Where is genetics leading us: The future of genetics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | UCL Teaching lecture - Neuromuscular Disease MSc/MRes Advanced genetic technologies and clinical applications module invited by David Blundred - Education Unit - Institute of Neurology |
Year(s) Of Engagement Activity | 2022 |
Description | invited interview |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interview to discuss the latest study in the Lancet which suggests By 2050, more than 153 million people could have dementia, up from 57 million in 2019, and that more than one in 50 people in Britain will be living with dementia by 2050. Public knowledge The interview in English, around 5min, aired on BBC World TV and ran several times in full. As a reminder BBC world TV has more than 122 million viewers a week and in more than 200 countries. Their website receives more than a billion views a month |
Year(s) Of Engagement Activity | 2022 |
Description | invited lecture 25th National Dementia Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | presentation - Alzheimer's disease: from genetic analysis to mechanistic treatments, with Q&A Thursday 9th February |
Year(s) Of Engagement Activity | 2023 |
Description | invited speaker - Understanding the endosomal pathway in neurodegeneration' |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Royal Society Hooke Discussion Meeting Organised by Professor Peter Cullen, Professor Peter St George-Hyslop FRS, Professor Scott Small and Dr Henne Holstege Understanding the endosomal network in neurodegeneration 21 - 22 November 2022 The Royal Society, London and online |
Year(s) Of Engagement Activity | 2022 |
Description | invited speaker 12th European Congress of Neuropathology |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Lecture entitled: Clues to the aetiology of neurodegenerative diseases from genomic analysis at 12th European Congress of Neuropathology |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.ecnp2020.dk/ |
Description | invited speaker Scientific Steering Committee of the Global Symposium on Lysosomal Storage Disorders (GSLSD) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | 1. Deliver a presentation on the theme of "Mechanisms that underly the relationships between specific gene defects and nervous system dysfunction/damage" 2. • Participate in an interactive live Q&A and panel discussion related to the question "Why is there high phenotypic variability in patients with the same lysosomal storage diseases? Is this any different from other monogenic diseases?" Scientific Steering Committee of the Global Symposium on Lysosomal Storage Disorders (GSLSD) |
Year(s) Of Engagement Activity | 2022 |
Description | talk on Genetics at McGill University in Canada |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invited Lecture |
Year(s) Of Engagement Activity | 2019 |
Description | talk to first virtual Congress of the Neurological Association of South Africa |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Two lectures for the first virtual Congress of the Neurological Association of South Africa 1. Genetic analysis of Alzheimer's and Parkinson's disease, damage response failure as the underlying problem of the disease 2. Genetic prediction of sporadic disease |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.nasacongresses.co.za/ |
Description | zoom IEU seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Invited lecture for MRC Integrative Epidemiology Unit (IEU) Seminar Series Title: Genomic analysis of neurodegeneration, University of Bristol |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.bristol.ac.uk/integrative-epidemiology/seminars/2020/seminar-john-hardy.html |